StockData
Precigen, Inc. logo

Precigen, Inc. (PGEN) stock

PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 2/30
$4.29−0.01 (-0.23%)

Close on Nov 17, 2026Market cap $1.54BP/E –Yield –

Precigen r&d expenses

Research and development expenses are spending on new products and technology.

Precigen's R&D Expenses for the twelve months ending Sep 30, 2019 was $379.57M, up 133.2% year over year. For fiscal 2025 it was $41.33M, down 22.1% from the year before. Over ten years it grew -5.2% a year on average. The highest annual figure on record is $404.59M in fiscal 2018.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$41.33M-22.1%
FY2024Dec 31, 2024$53.07M+9.2%
FY2023Dec 31, 2023$48.61M-88.0%
FY2018Dec 31, 2018$404.59M+182.5%
FY2017Dec 31, 2017$143.21M+27.7%
FY2016Dec 31, 2016$112.14M-24.0%
FY2015Dec 31, 2015$147.48M+150.0%
FY2014Dec 31, 2014$58.98M+22.5%
FY2013Dec 31, 2013$48.14M-24.8%
FY2012Dec 31, 2012$64.03M-8.8%
FY2011Dec 31, 2011$70.23M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$7.28M-76.9%
Q1 FY2026Mar 31, 2026$5.64M-83.7%
Q2 FY2025Jun 30, 2025$11.49M-65.3%
Q1 FY2025Mar 31, 2025$10.48M-96.3%
Q3 FY2019Sep 30, 2019$31.48M-29.9%
Q2 FY2019Jun 30, 2019$34.52M-17.9%
Q1 FY2019Mar 31, 2019$33.06M-11.3%
Q4 FY2018Dec 31, 2018$280.51M+627.8%
Q3 FY2018Sep 30, 2018$44.89M+23.1%
Q2 FY2018Jun 30, 2018$42.05M+23.6%
Q1 FY2018Mar 31, 2018$37.27M+9.0%
Q4 FY2017Dec 31, 2017$38.54M+33.5%
Q3 FY2017Sep 30, 2017$36.47M+25.6%
Q2 FY2017Jun 30, 2017$34.01M–
Q1 FY2017Mar 31, 2017$34.18M–
Q4 FY2016Dec 31, 2016$28.87M–
Q3 FY2016Sep 30, 2016$29.04M–

More Precigen figures

See a number that looks wrong?